Clinical · Prescriber conversations · continued

How to ask for a dose change without antagonising anyone — what changed since posts 91–93

Clinical › Prescriber conversations prior authorisation telehealth type 2 diabetes Solved

This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1 · go to the accepted answer.

v.kjaerTL2 Moderator23 Nov 2024#91

Discussing off-label dosing: if you want to dose differently than the label specifies (slower titration, higher final dose), discussing that explicitly and understanding the clinician's reasoning is better than self-prescribing.

30 likes 20mo

d.bramleyTL323 Nov 2024#92

Collapsed as off-topic by two members at trust level 3 or above

Picking up post #89: that is the part I would want checked first.

Understanding stopping rules: what would prompt stopping the compound? Adverse effect, lack of benefit after a defined time, or other reasons? Knowing in advance is better than surprise discontinuation.

a.nascimentoTL2 Moderator23 Nov 2024#93

r.szabo, post #42: Clarifying indication: if a compound is approved for diabetes but you have obesity without diabetes, clarify whether your clinician considers this off-label use and what the evidence basis is. Go to post

Clarifying indication: if a compound is approved for diabetes but you have obesity without diabetes, clarify whether your clinician considers this off-label use and what the evidence basis is.

6 likes in reply to #42 20mo

This topic was referenced in

[2026 update] What a good consultation looks like from the other sideClinical › Prescriber conversations · 36 replies

Suggested topics

Topic	Participants	Replies	Views	Activity
Asking about a compound your prescriber has not heard of — one year on Clinical › Prescriber conversations beginner friendly type 2 diabetes prior authorisation Solved Under review On the subject in the title: Asking about a compound your prescriber has not heard of — one year on Working notes rather than a conclusion. General question, not a request for advice about my own care — I…	+11	15	3.7k	19mo
Coming back to: Preparing for an appointment: one page, three questions Clinical › Prescriber conversations prior authorisation type 2 diabetes telehealth Posting this under the heading it deserves: Preparing for an appointment: one page, three questions Everything below is what sits behind that. General question, not a request for advice about my own care — I…	+139	151	47k	18mo
Getting a referral rather than a refusal Clinical › Prescriber conversations telehealth beginner friendly type 2 diabetes Getting a referral rather than a refusal — setting out what I have, and where I think it stops being reliable. General question, not a request for advice about my own care — I know the difference and I would…	+8	12	32k	2mo
Discussing something you have already been doing Clinical › Prescriber conversations prior authorisation type 2 diabetes beginner friendly telehealth Solved Under review On the subject in the title: Discussing something you have already been doing Working notes rather than a conclusion. General question, not a request for advice about my own care — I know the difference and I…	+10	14	3.4k	10mo
What to bring: records that a clinician can actually use — a second dataset Clinical › Prescriber conversations telehealth beginner friendly prior authorisation What to bring: records that a clinician can actually use — a second dataset I have a specific reason for asking rather than idle curiosity, and the context is below. Asking about a population rather than…	+80	86	5.6k	3h

Related topics — sharing the tags prior authorisation, telehealth, type 2 diabetes

Topic	Participants	Replies	Views	Activity
Is there a ceiling dose beyond which semaglutide stops adding benefit? Compounds › Semaglutide effect size type 2 diabetes SELECT trial Is there a ceiling dose beyond which semaglutide stops adding benefit? I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen SURPASS-4 ( Lancet , 2021) cited in…		2	14k	2mo
Revisiting: Reading a denial letter as a specification for your appeal Access › Insurance & coverage prior authorisation insurance formulary appeals Posting this under the heading it deserves: Revisiting: Reading a denial letter as a specification for your appeal Everything below is what sits behind that. A coverage question with the paperwork detail…	+125	138	9.4k	10mo
What the published dose-response for semaglutide actually looks like above 2.4 mg Compounds › Semaglutide STEP programme type 2 diabetes effect size SELECT trial Solved What the published dose-response for semaglutide actually looks like above 2.4 mg — that is the question, and I have not found it answered plainly anywhere I have looked. Session topic: SURMOUNT-4 ( JAMA ,…		2	10k	3mo
Semaglutide half-life: where the 165 to 184 hour figure comes from Compounds › Semaglutide semaglutide effect size randomised trial type 2 diabetes Wiki Semaglutide half-life: where the 165 to 184 hour figure comes from — setting out what I have, and where I think it stops being reliable. Comparing FLOW ( N Engl J Med , 2024) with STEP 4 ( JAMA , 2021) and…	+128	145	3k	4mo
Molecular mass of semaglutide and why the figure differs between sources Compounds › Semaglutide SELECT trial effect size semaglutide STEP programme Molecular mass of semaglutide and why the figure differs between sources — setting out what I have, and where I think it stops being reliable. Comparing SURMOUNT-2 ( Lancet , 2023) with STEP 4 ( JAMA , 2021)…	+101	110	12k	16h